MF management.
作者信息
Bose Prithviraj, Verstovsek Srdan
机构信息
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, United States.
出版信息
Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000210. eCollection 2019 Jun.
Abstract
摘要
相似文献
1
MF management.蕈样肉芽肿的管理
Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000210. eCollection 2019 Jun.
2
Treatment and management of myelofibrosis in the era of JAK inhibitors.JAK抑制剂时代骨髓纤维化的治疗与管理
Biologics. 2013;7:189-98. doi: 10.2147/BTT.S34942. Epub 2013 Aug 20.
3
Periparturient climatic, animal, and management factors influencing the incidence of milk Fever in grazing systems.围产期气候、动物及管理因素对放牧系统中乳热发病率的影响
J Dairy Sci. 2006 Jul;89(7):2775-83. doi: 10.3168/jds.S0022-0302(06)72354-2.
4
[Financial management of clinical cardiovascular research in France from 1985 to 1990].[1985年至1990年法国临床心血管研究的财务管理]
Arch Mal Coeur Vaiss. 1992 Sep;85(9):1329-34.
5
Balloon-assisted maturation for arteriovenous fistula maturation failure: an early period experience.球囊辅助成熟术治疗动静脉内瘘成熟失败：早期经验
Ann Surg Treat Res. 2016 May;90(5):272-8. doi: 10.4174/astr.2016.90.5.272. Epub 2016 May 2.
6
What is pre-fibrotic myelofibrosis and how should it be managed in 2018?什么是前纤维化骨髓纤维化，2018 年应如何治疗？
Br J Haematol. 2018 Oct;183(1):23-34. doi: 10.1111/bjh.15562. Epub 2018 Oct 17.
7
Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies.骨髓纤维化相关性贫血：当前及新出现的治疗策略
Hemasphere. 2017 Dec 20;1(1):e1. doi: 10.1097/HS9.0000000000000001. eCollection 2017 Dec.
8
An expert consensus report on mycosis fungoides in Italy: epidemiological impact and diagnostic-therapeutic pathway.
Ital J Dermatol Venerol. 2021 Aug;156(4):413-421. doi: 10.23736/S2784-8671.20.06668-7. Epub 2021 May 26.
9
Association between metabolic diseases and the culling risk of high-yielding dairy cows in a transition management facility using survival and decision tree analysis.应用生存分析和决策树分析研究过渡管理设施中高产奶牛淘汰风险与代谢疾病之间的关系。
J Dairy Sci. 2018 Oct;101(10):9419-9429. doi: 10.3168/jds.2018-14422. Epub 2018 Aug 16.
10
Mycosis fungoides in pediatric patients: Clinical features, diagnostic challenges, and advances in therapeutic management.儿童蕈样肉芽肿：临床特征、诊断挑战及治疗管理进展
Pediatr Dermatol. 2020 Jan;37(1):18-28. doi: 10.1111/pde.14026. Epub 2019 Oct 20.
引用本文的文献
1
Novel treatments for myelofibrosis: beyond JAK inhibitors.骨髓纤维化的新型治疗方法：超越JAK抑制剂
Int J Hematol. 2022 May;115(5):645-658. doi: 10.1007/s12185-022-03299-8. Epub 2022 Feb 19.
本文引用的文献
1
New Concepts of Treatment for Patients with Myelofibrosis.骨髓纤维化患者的治疗新概念。
Curr Treat Options Oncol. 2019 Jan 24;20(1):5. doi: 10.1007/s11864-019-0604-y.
2
Prefibrotic myelofibrosis: treatment algorithm 2018.原幼纤维化：2018 年治疗算法。
Blood Cancer J. 2018 Nov 7;8(11):104. doi: 10.1038/s41408-018-0142-z.
3
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.一项评估芦可替尼联合阿扎胞苷治疗骨髓纤维化患者的 2 期研究。
Blood. 2018 Oct 18;132(16):1664-1674. doi: 10.1182/blood-2018-04-846626. Epub 2018 Sep 5.
4
Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.鲁索替尼再激发可改善骨髓纤维化患者的全身症状和脾肿大：病例系列
Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e463-e468. doi: 10.1016/j.clml.2018.06.025. Epub 2018 Jun 28.
5
U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions.原发性骨髓纤维化中的U2AF1突变类型：表型和预后差异
Leukemia. 2018 Oct;32(10):2274-2278. doi: 10.1038/s41375-018-0078-0. Epub 2018 Feb 27.
6
Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.原发性骨髓纤维化的修订细胞遗传学危险分层：基于 1002 例信息性患者的分析。
Leukemia. 2018 May;32(5):1189-1199. doi: 10.1038/s41375-018-0018-z. Epub 2018 Feb 2.
7
Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.进退两难：评估芦可替尼停药后骨髓纤维化的挽救治疗及预后
Ann Hematol. 2018 Mar;97(3):435-441. doi: 10.1007/s00277-017-3194-4. Epub 2017 Nov 30.
8
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.芦可替尼停药后骨髓纤维化的克隆进化与结局
Blood. 2017 Aug 31;130(9):1125-1131. doi: 10.1182/blood-2017-05-783225. Epub 2017 Jul 3.
9
Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.鲁索替尼治疗临床获益的实用衡量指标：COMFORT-I的探索性分析
Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):479-487. doi: 10.1016/j.clml.2017.05.015. Epub 2017 May 12.
10
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.一个临床-分子预后模型，用于预测真性红细胞增多症后和特发性血小板增多症后骨髓纤维化患者的生存情况。
Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31.
Zotero 插件